[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612446":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":37,"responsibleParty":64,"collaborators":68,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":79,"sex":85,"minAge":86,"maxAge":26,"enrollmentInfo":87,"targetDuration":26,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"No rifampin","EXPERIMENTAL","These patients will not receive adjunctive rifampin.",[13],"Other: No rifampin",{"label":15,"type":16,"description":17,"interventionNames":18},"Adjunctive rifampin","ACTIVE_COMPARATOR","These patients will receive adjunctive rifampin as recommended in guidelines.",[19],"Drug: Rifampin",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Rifampin","Patients will receive rifampin 900mg a day in 2-3 divided doses",[15],null,{"type":6,"name":9,"description":28,"armGroupLabels":29,"otherNames":26},"Subjects will be assigned to not receive adjunctive rifampin",[9],[31],{"name":32,"role":33,"phone":34,"phoneExt":35,"email":36},"Lina Petrella","CONTACT","514-934-1934","23730","lina.petrella@affiliate.mcgill.ca",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)","RECRUITING","Montreal","Quebec","H4A4S1","Canada","CA",{"type":47,"coordinates":48},"Point",[49,50],-73.58781,45.50884,{"lat":50,"lon":49},[53,56,59,61],{"name":32,"role":33,"phone":54,"phoneExt":35,"email":55},"15149341934","todd.lee@mcgill.ca",{"name":57,"role":58,"phone":26,"phoneExt":26,"email":26},"Todd C Lee, MD MPH FIDSA","PRINCIPAL_INVESTIGATOR",{"name":60,"role":58,"phone":26,"phoneExt":26,"email":26},"Emily G McDonald, MD MSc",{"name":62,"role":63,"phone":26,"phoneExt":26,"email":26},"Matthew P. Cheng, MD MSc","SUB_INVESTIGATOR",{"type":65,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Todd C. Lee MD MPH FIDSA","Professor of Medicine",[69,70,73,75],{"name":5,"class":6},{"name":71,"class":72},"Canadian Institutes of Health Research (CIHR)","OTHER_GOV",{"name":74,"class":6},"University of Melbourne",{"name":76,"class":6},"The Peter Doherty Institute for Infection and Immunity","100612446","phase-3-adjunctive-rifampin-for-the-treatment-of-prosthetic-valve-endocarditis-due-to-s-aureus-100612446",false,"NCT07253688","Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus","Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus (RIFA-SNAP)","RIFA-SNAP","Inclusion Criteria:\n\n1. Probable or definite prosthetic valve endocarditis involving the tricuspid, pulmonic, mitral and\u002For aortic valves by the 2023 Duke-ISCVID Criteria (including Cardiac PET evidence if applicable);\n2. Patient or healthcare proxy provide informed consent.\n\nExclusion Criteria:\n\n1. Death deemed imminent and inevitable within days or patient will be receiving palliative care and has prognosis \\\u003C 90 days according to the treating team;\n2. Patient requires intensive care but has a do not resuscitate order precluding transfer;\n3. Polymicrobial bacteremia (not including skin commensals or other recognized contaminant);\n4. Organism tests as rifampin resistant;\n5. History of hypersensitivity\u002Fanaphylaxis or severe adverse reaction to rifampin;\n6. Category X or other important drug-drug interaction with rifampin which cannot be safely mitigated \\[with as-needed consultation from experts from pharmacy and\u002For internal medicine\u002Fgeriatrics for potential deprescribing\\];\n7. Child Pugh Class C cirrhosis;\n8. Clinician deems rifampin to be mandatory;\n9. Patient has already received \\>3 days of rifampin at time of screening or \\>10 days of total therapy\n10. Pregnancy or breast feeding\n\nAdministrative exclusions:\n\n1. No reliable means of outpatient contact (telephone\u002Femail\u002Ftext);\n2. Previously enrolled;\n3. Prior S. aureus bacteremia within the preceding 180 days","ALL","18 Years",{"count":88,"type":89},330,"ESTIMATED","INTERVENTIONAL",[92],"PHASE3","This is a sub-study of the S. aureus Network Adaptive Platform (SNAP) trial (NCT05137119) wherein we will evaluate whether not giving rifampin in patients with probable or definite prosthetic valve endocarditis due to S. aureus is non-inferior to giving rifampin.",[95,96],"Staphylococcus Aureus Endocarditis","Prosthetic Valve Endocarditis",[98,99,23],"S. aureus bacteremia","Prosthetic valve endocarditis","2025-12-04",{"date":102,"type":103},"2025-12-10","ACTUAL",{"date":105,"type":103},"2025-11-10",{"date":107,"type":89},"2030-07",{"name":66,"class":6},1]